Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Drug Development Platform Creating Novel Antiviral Therapeutics for Pandemics and Seasonal Influenza with Sam Lee and Jim Martin Cocrystal Pharma TRANSCRIPT
Download PDFMay 8, 2022
Sam Lee, interim Co-CEO and President, and Jim Martin, interim Co-CEO and CFO of Cocrystal Pharma. They're a clinical stage biotech company using their proprietary drug development platform to create novel antiviral therapeutics to treat seasonal influenza and pandemic viral infections like COVID-19.
Jim explains, "There are vaccines, and then there are therapeutics. We are a therapeutic company. We don't produce vaccines. Vaccines are more preventative. What we do is, once you get the illness, we stop the illness through our compounds. So as a therapeutic, you do need that one-two punch of both vaccines and therapeutics. And in the case of influenza, we have every year people getting vaccines, which are good. But the therapeutics that are necessary are far and few between."
Sam elaborates, "So our compounds, the compound IDs of CC-42344, we're currently doing phase one study in Australia, this compound has an outstanding drug-resistant profile. We have not been able to isolate the drug-resistance strains from in vitro test-tube experiments. So we believe this compound is really designed for the pandemic as well as a seasonal treatment, particularly targeting for influenza A infection. And also, because of the excellent drug resistance profile, we believe this would be a real breakthrough influenza treatment for pandemic as well as seasonal infection."
@CocrystalPharma #Flu #Influenza #Pandemic #SeasonalFlu #COVID #Vaccines #COVIDTreatments #FluTreatments
